信函：倾向评分——谨慎处理。 - Suppr

Letter: propensity score-handle with care.

作者信息

Macaluso Fabio Salvatore, Orlando Ambrogio

机构信息

IBD Unit, ''Villa Sofia-Cervello'' Hospital, Palermo, Italy.

出版信息

Aliment Pharmacol Ther. 2021 Jan;53(2):360-361. doi: 10.1111/apt.16179.

DOI:10.1111/apt.16179

PMID:33368517

Abstract

摘要

相似文献

Letter: propensity score-handle with care.

Aliment Pharmacol Ther. 2021 Jan;53(2):360-361. doi: 10.1111/apt.16179.

Letter: propensity score-handle with care. Authors' reply.

Aliment Pharmacol Ther. 2021 Jan;53(2):362-363. doi: 10.1111/apt.16211.

Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail.

Aliment Pharmacol Ther. 2020 Aug;52(3):561-562. doi: 10.1111/apt.15862.

Letter: ustekinumab for the treatment of post-surgical and refractory Crohn's disease.

Aliment Pharmacol Ther. 2021 Apr;53(7):859-860. doi: 10.1111/apt.16281.

Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. Authors' reply.

Aliment Pharmacol Ther. 2020 Aug;52(3):563-564. doi: 10.1111/apt.15888.

Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth?

Aliment Pharmacol Ther. 2020 Oct;52(7):1253-1254. doi: 10.1111/apt.16009.

Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth. Authors' reply.

Aliment Pharmacol Ther. 2020 Oct;52(7):1255-1256. doi: 10.1111/apt.16062.

Letter: ustekinumab's effectiveness outcomes compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers?

Aliment Pharmacol Ther. 2020 Aug;52(4):751-752. doi: 10.1111/apt.15920.

Letter: ustekinumab's effectiveness compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers? Authors' reply.

Aliment Pharmacol Ther. 2020 Aug;52(4):753-754. doi: 10.1111/apt.15959.

The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor.

Aliment Pharmacol Ther. 2020 May;51(10):948-957. doi: 10.1111/apt.15706. Epub 2020 Apr 6.

引用本文的文献

Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience.

Therap Adv Gastroenterol. 2021 May 3;14:17562848211010668. doi: 10.1177/17562848211010668. eCollection 2021.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Letter: propensity score-handle with care.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Letter: propensity score-handle with care.

作者信息

机构信息

出版信息

相似文献

引用本文的文献